Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Towa Pharmaceutical Co., Ltd. (4553:JPX), powered by AI.
Towa Pharmaceutical Co., Ltd. is currently trading at ¥3,915. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Towa Pharmaceutical Co., Ltd. on Alpha Lenz.
Towa Pharmaceutical Co., Ltd.'s P/E ratio is 10.2.
“Towa Pharmaceutical Co., Ltd. trades at a P/E of 10.2 (undervalued) with solid ROE of 11.6%. 3Y revenue CAGR of 16.2% highlights clear growth momentum.”
Ask for details →Towa Pharmaceutical Co., Ltd. is a notable entity within the pharmaceutical industry, primarily focused on the research, development, manufacture, and distribution of generic medicines. These cost-effective alternatives to branded products play a critical role in healthcare by making treatments more accessible and affordable to patients worldwide. Based in Japan, Towa Pharmaceutical Co., Ltd. operates in domestic and international markets, delivering a wide range of pharmaceuticals that cover various therapeutic areas including cardiology, endocrinology, and infectious diseases. The company is particularly significant in the generics sector, where it leverages extensive manufacturing capabilities and a commitment to quality assurance, ensuring that its products meet stringent regulatory standards. Towa's impact on the market is underscored by its contribution to reducing healthcare costs and its involvement in collaborations with medical professionals to enhance patient outcomes. By expanding the availability of essential medications, Towa Pharmaceutical Co., Ltd. serves as a vital player in addressing global health challenges.
“Towa Pharmaceutical Co., Ltd. trades at a P/E of 10.2 (undervalued) with solid ROE of 11.6%. 3Y revenue CAGR of 16.2% highlights clear growth momentum.”
Ask for details →Towa Pharmaceutical Co., Ltd. (ticker: 4553) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 4,788 employees. Market cap is $192.7B.
The current price is 3,915 with a P/E ratio of 10.15x and P/B of 1.12x.
ROE is 11.59% and operating margin is 8.95%. Annual revenue is $259.6B.